US EditionApple Will Appeal $634M Jury Verdict in Patent Claim by Masimo Corp.
A federal jury in California awarded Masimo $634 million for Apple’s use of patented blood-oxygen monitoring technology, reviving a potential import ban on Apple Watches.
- On Friday, a federal jury in California ordered Apple, iPhone-maker, to pay Masimo, US medtech company, $634 million for infringing blood-oxygen monitoring technology.
- Masimo launched its lawsuit after Apple's Series 6 watch added a blood-oxygen feature, alleging misuse of proprietary pulse-oximetry technology and improper recruitment of its chief medical officer.
- Removing the feature, Apple updated Watches in 2024 to avoid a permanent ban after the US International Trade Commission banned imports, and earlier this year reintroduced a tweaked feature.
- Legal aftermath: Apple plans to appeal while Masimo vows to defend its IP; the US International Trade Commission will examine if redesigned Watches still infringe patents and aims to complete the probe within six months.
- Masimo's technology is primarily designed for hospital use and licensed by Philips, Atom, and GE Healthcare, while Apple has faced related countersuits and Apple said `The single patent in this case expired in 2022 and is specific to historic patient-monitoring technology from decades ago.
19 Articles
19 Articles
Apple ordered to pay Masimo $634 million in Apple Watch patent dispute, ban threat returns
Masimo launched a lawsuit against Apple in 2020 after the launch of the Series 6 watch with its blood oxygen monitoring feature. Masimo claimed that the tech giant used proprietary pulse-oximetry technology in the wearable, infringing a number of its patents. Masimo also claimed Apple had improperly recruited its staff...Read Entire Article
US Jury Orders Apple To Pay $634M In Patent Lawsuit
What happens when a tech giant goes head-to-head with a medical-tech heavyweight? In California, a jury just answered that question — and it cost Apple a staggering $634 million.The verdict sided with Masimo, a company known for its medical-monitoring tech. It argued that certain Apple Watch features — like workout mode and heart-rate alerts — relied on its patented blood-oxygen technology.And according to the jury, Masimo was right.Apple Watche…
Apple’s $634 Million Watch Wound: Inside the Masimo Patent Verdict
In a stunning blow to Apple Inc., a federal jury in California has ordered the tech giant to pay medical device maker Masimo Corp. $634 million for infringing on a patent related to blood-oxygen monitoring technology in the Apple Watch. The verdict, delivered on November 15, 2025, marks a significant escalation in the long-simmering legal battle between the two companies, which has already led to import bans and feature disables in the U.S. mark…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
